Comparative Study of an Ondansetron and a Ramosetron an Aprepitant in the Control of Nausea and Vomiting in Gynecologinc Cancer Patient with Chemotherapy원문보기
ResultsThe efficacy of controlling nausea with an ondansetron regimen and a ramosetron regimen and an aprepitant regimen was 85.29%, 78.26%, 80% in acute periods (P-value = 0.037) and 88.23%, 98.26%, 87.5% in delayed periods (P-value = 0.000), respectively. The efficacy of controlling vomiting with ...
ResultsThe efficacy of controlling nausea with an ondansetron regimen and a ramosetron regimen and an aprepitant regimen was 85.29%, 78.26%, 80% in acute periods (P-value = 0.037) and 88.23%, 98.26%, 87.5% in delayed periods (P-value = 0.000), respectively. The efficacy of controlling vomiting with an ondansetron regimen and a ramosetron regimen and an aprepitant regimen and an ondansetron regimen was 82.35%, 97.3%, 90% in acute periods (P-value=0.002) and 82.35%, 100%, 95% in delayed periods (P-value = 0.000), respectively. The common adverse effects in each groups were not significantly. ConclusionsAppropriate to each patient’s symptoms, the choice of drugs will be needed since each of the drugs have different effects on vomiting. Even though the each antiemetic drug has good efficacy, the effect of the drug is not complete. Therefore the use of additional drugs are also needed. ObjectivesChemotherapy induced nausea and vomiting is most distressing adversed effects in gynecologic cancer patients receiving chemotherapy. we compared effectiveness of ondansetron and ramosetron and aprepitant for optimal antiemetic treatment in gynecologic cancer patient receiving chemotherapy. MethodsThe study was performed retrospective on 189 patients who was diagnosed initially the gynecological cancer during chemotherapy at Kosin university hospital between January 2008 and December 2010. The efficacy of controlling acute/delayed nausea and vomiting were analyzed by counting numbers of nausea and vomiting reported in medical records of 189 patient receiving cisplatin-based chemotherapy. Statistical analysis was performed using the ANOVA and Fisher’s exact chi-square test. ResultsThe efficacy of controlling nausea with an ondansetron regimen and a ramosetron regimen and an aprepitant regimen was 85.29%, 78.26%, 80% in acute periods (P-value = 0.037) and 88.23%, 98.26%, 87.5% in delayed periods (P-value = 0.000), respectively. The efficacy of controlling vomiting with an ondansetron regimen and a ramosetron regimen and an aprepitant regimen and an ondansetron regimen was 82.35%, 97.3%, 90% in acute periods (P-value=0.002) and 82.35%, 100%, 95% in delayed periods (P-value = 0.000), respectively. The common adverse effects in each groups were not significantly. ConclusionsAppropriate to each patient’s symptoms, the choice of drugs will be needed since each of the drugs have different effects on vomiting. Even though the each antiemetic drug has good efficacy, the effect of the drug is not complete. Therefore the use of additional drugs are also needed.
ResultsThe efficacy of controlling nausea with an ondansetron regimen and a ramosetron regimen and an aprepitant regimen was 85.29%, 78.26%, 80% in acute periods (P-value = 0.037) and 88.23%, 98.26%, 87.5% in delayed periods (P-value = 0.000), respectively. The efficacy of controlling vomiting with an ondansetron regimen and a ramosetron regimen and an aprepitant regimen and an ondansetron regimen was 82.35%, 97.3%, 90% in acute periods (P-value=0.002) and 82.35%, 100%, 95% in delayed periods (P-value = 0.000), respectively. The common adverse effects in each groups were not significantly. ConclusionsAppropriate to each patient’s symptoms, the choice of drugs will be needed since each of the drugs have different effects on vomiting. Even though the each antiemetic drug has good efficacy, the effect of the drug is not complete. Therefore the use of additional drugs are also needed. ObjectivesChemotherapy induced nausea and vomiting is most distressing adversed effects in gynecologic cancer patients receiving chemotherapy. we compared effectiveness of ondansetron and ramosetron and aprepitant for optimal antiemetic treatment in gynecologic cancer patient receiving chemotherapy. MethodsThe study was performed retrospective on 189 patients who was diagnosed initially the gynecological cancer during chemotherapy at Kosin university hospital between January 2008 and December 2010. The efficacy of controlling acute/delayed nausea and vomiting were analyzed by counting numbers of nausea and vomiting reported in medical records of 189 patient receiving cisplatin-based chemotherapy. Statistical analysis was performed using the ANOVA and Fisher’s exact chi-square test. ResultsThe efficacy of controlling nausea with an ondansetron regimen and a ramosetron regimen and an aprepitant regimen was 85.29%, 78.26%, 80% in acute periods (P-value = 0.037) and 88.23%, 98.26%, 87.5% in delayed periods (P-value = 0.000), respectively. The efficacy of controlling vomiting with an ondansetron regimen and a ramosetron regimen and an aprepitant regimen and an ondansetron regimen was 82.35%, 97.3%, 90% in acute periods (P-value=0.002) and 82.35%, 100%, 95% in delayed periods (P-value = 0.000), respectively. The common adverse effects in each groups were not significantly. ConclusionsAppropriate to each patient’s symptoms, the choice of drugs will be needed since each of the drugs have different effects on vomiting. Even though the each antiemetic drug has good efficacy, the effect of the drug is not complete. Therefore the use of additional drugs are also needed.
참고문헌 (19)
Comparative study of an aprepitant regimen with an ondansetron regimen, for efficacy in gynecological cancer patients with chemotherapy 538 2009
Theinfluence of symptoms of vomiting with cytotoxic chemotherapy Richardson 1746 1988
Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomized trial of antiemetics Morran 1323 1979
Control of cancer chemotherapy induced nausea and vomiting Harmon 2642 1984
Double blind placebo controlled study of metoclopramide Hmosley 250 1982
Extrapyramidal rreactions with metocloprimide Bateman 930 1982
Roila, Fausto, Donati, Donatella, Tamberi, Stefano, Margutti, Guido.
Delayed emesis: incidence, pattern, prognostic factors and optimal treatment.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,
vol.10,
no.2,
88-95.
Hesketh, P.J., Van Belle, S., Aapro, M., Tattersall, F.D., Naylor, R.J., Hargreaves, R., Carides, A.D., Evans, J.K., Horgan, K.J..
Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.
European journal of cancer,
vol.39,
no.8,
1074-1080.
Hesketh, Paul J., Grunberg, Steven M., Gralla, Richard J., Warr, David G., Roila, Fausto, de Wit, Ronald, Chawla, Sant P., Carides, Alexandra D., Ianus, Juliana, Elmer, Mary E., Evans, Judith K., Beck, Klaus, Reines, Scott, Horgan, Kevin J..
The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin-The Aprepitant Protocol 052 Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
vol.21,
no.22,
4112-4119.
Poli-Bigelli, Sergio, Rodrigues-Pereira, Jose, Carides, Alexandra D., Julie Ma, Guoguang, Eldridge, Krista, Hipple, Anita, Evans, Judith K., Horgan, Kevin J., Lawson, Francesca.
Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting : Results from a randomized, double-blind, placebo-controlled trial in Latin America.
Cancer,
vol.97,
no.12,
3090-3098.
Leibundgut, U., Lancranjan, I..
FIRST RESULTS WITH ICS 205-930 (5-HT3 RECEPTOR ANTAGONIST) IN PREVENTION OF CHEMOTHERAPY-INDUCED EMESIS.
The Lancet,
vol.329,
no.8543,
1198-.
Clinical and methodological issues in antiemetic therapy: a worldwide survey of experts' opinions. Multinational Association of Supportive Care in Cancer Ballatori 269 1997
10.1002/1097-0142(19941001)74
Clinical and methodological issues in antiemetic therapy: a worldwide survey of experts' opinions. Multinational Association of Supportive Care in Cancer Ballatori 269 1997
Metoclopramide. A review of antiemetic trials Gralla 63 1983
Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Gralla 2971 2002
Roila, F, Tonato, M, Cognetti, F, Cortesi, E, Favalli, G, Marangolo, M, Amadori, D, Bella, M A, Gramazio, V, Donati, D.
Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone..
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
vol.9,
no.4,
675-678.
A Phase III Study of Ondansetron & Metoclopramide in the Management of Cisplatin-Induced Emesis Min 542 1994
A Randomized Comparison of Tropisetron versus Ondansetron in the Control of Nausea and Vomiting in Gynecologic Cancer Patients Undergone Cisplatin-Based Chemotherapy Kim 2544 1998
AI-Helper
※ AI-Helper는 부적절한 답변을 할 수 있습니다.